• Myelodysplastic syndrome (MDS) is a rare disease in children and the treatment option before the allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rarely reported. (nih.gov)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) in thalassemia remains a challenge. (nih.gov)
  • In conclusion, the 30-year survival rate of ex-thalassemia patients after HSCT was similar to that expected in CT thalassemia patients, with the vast majority of HSCT survivors cured from thalassemia. (nih.gov)
  • Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. (wikipedia.org)
  • Infection and graft-versus-host disease are major complications of allogeneic HSCT. (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • For other cancers such as acute myeloid leukemia, though, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, so the allogeneic treatment may be preferred for those conditions. (wikipedia.org)
  • Allogeneic bone marrow or hematopoietic stem cell transplantation (HSCT) may be helpful for patients with SCID. (medscape.com)
  • Patients with other immunodeficiency syndromes may benefit from bone marrow transplantation or HSCT, including those with WAS or XHM. (medscape.com)
  • Advances in critical care that have resulted in a significant decrease in MUD-HSCT transplant-related mortality and an increase in the survival of SCID infants who are severely infected at the time of diagnosis. (medscape.com)
  • Early diagnosis before the development of permanent lung and liver damage and referral to a specialized center for bone marrow transplantation/HSCT are essential for therapeutic success. (medscape.com)
  • Recently, we and others have shown that allogeneic hematopoietic stem cell transplantation (allo-HSCT) may represent a valid treatment option in leukemic myeloid sarcoma. (haematologica.org)
  • Serum citrulline was quantified by liquid chromatography in blood samples collected from consecutive patients who received an allogeneic HSCT in our institution between July 2014 and November 2019. (confex.com)
  • When hematopoietic stem cell transplant (HSCT) is necessary for children with acute myeloid leukemia (AML), there remains debate about the best stem cell source. (duke.edu)
  • OSAKA, Japan & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Takeda ( TSE:4502/NYSE:TAK ) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo. (businesswire.com)
  • Lower GI aGvHD represents a critical unmet need in patients undergoing allo-HSCT," said Yi-Bin Chen, MD, Director, Hematopoietic Cell Transplant & Cell Therapy Program, Mass General Cancer Center. (businesswire.com)
  • Recent advances in flow cytometric and molecular measurable residual disease detection have further enhanced modern risk-stratified approaches to chemotherapy and allocation to allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) when indicated. (haematologica.org)
  • The purpose of this study is to evaluate the effectiveness of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. (mayo.edu)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • Background: Post-transplant relapse has a dismal prognosis in children with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). (istinye.edu.tr)
  • Right now, hematopoietic stem cell transplantation (HSCT) is the foremost dependable healing treatment with amazing comes about for patients with HLAmatched family or disconnected givers. (alliedacademies.org)
  • We performed a review chart audit of 12 children who experienced allogeneic HSCT for WAS to report our involvement. (alliedacademies.org)
  • Thus, indeed with a critical rate of blended chimerism, HSCT gives considerable advantage to WAS patients, with amazing by and large survival [ 2 ]. (alliedacademies.org)
  • In patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), however, EFS and OS were not significantly different between FHL2 or iASPP high- and low-expression groups. (nature.com)
  • In a previous large cohort study, we investigated the cumulative incidence, risk factors, and clinical characteristics of BO in the modern landscape of allogeneic HSCT with a frequent use of a haploidentical donor and post-transplant cyclophosphamide for GVHD prophylaxis (Kulagin E. et al. (cttjournal.com)
  • We retrospectively analyzed the outcomes of 136 consecutive patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center. (qxmd.com)
  • One-year survival post-HSCT was 94% in ND-AML and 78% in R/R-AML. (bjh.be)
  • Results from a phase 2 study showed that a 2-step induction regimen involving dasatinib and intensive chemotherapy was associated with high rates of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients younger than 65 years with Philadelphia chromosome-positive (Ph+), newly diagnosed acute lymphoblastic leukemia (ALL), as well as improved 3-year overall survival (OS) rates for those undergoing allo-HSCT compared with those who did not. (cancertherapyadvisor.com)
  • Secondary study endpoints included HCR, safety, and the efficacy of allo-HSCT (ie, relapse-free survival, relapse rate, and non-relapse mortality). (cancertherapyadvisor.com)
  • In their concluding remarks, the study authors noted that "this study demonstrated [dasatinib]-combined 2-step induction improved pretransplant treatment, which facilitated [allo-HSCT] and resulted in significantly improved survival. (cancertherapyadvisor.com)
  • CMV infection is one of most frequent infectious complications in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). (cttjournal.com)
  • Despite treatment of CMV infection with antiviral drugs, CMV reactivation remains a major problem because it reduces the overall survival of patients after allo-HSCT. (cttjournal.com)
  • Figure 1 shows the number of CMV-specific T cells at the day +30 after allo-HSCT in patients with various modes of GVHD prophylaxis. (cttjournal.com)
  • Patients with more "aggressive" GVHD prophylaxis regimens (based on the use of high doses of post-transplant cyclophosphamide, T-cell depletion) have less CMV-specific T cells at +30 days after allo-HSCT. (cttjournal.com)
  • The "dot plot" shows the results of the study of CMV-specific T cells in one of the patients with T-depletion at +30 days after HSCT. (cttjournal.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment for MF. (antengene.com)
  • Most of the MN patients (77.3%) received hypomethylating agents with unsatisfactory response, and four had allogeneic hematopoietic stem cell transplantation (HSCT). (bloodcancerstoday.com)
  • 82%), with 39% progressing to allogeneic HSCT. (bloodcancerstoday.com)
  • In this study, we sought to describe characteristics, risk factors, and outcomes of Rhodococcus infection among solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients in the United States. (cdc.gov)
  • Allogeneic and autologous HSCT recipients were matched to recipients of the same type. (cdc.gov)
  • Six patients underwent HSCT (5 allogeneic, 1 autologous) and 12 SOT (4 heart, 4 lung, 3 kidney, 1 liver). (cdc.gov)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • In the section on aspergillosis, the revised recommendations include the use of a room with high-efficiency particulate air filters rather than laminar airflow as the protective environment for allogeneic HSCT recipients and the use of high-efficiency respiratory-protection devices (e.g. (cdc.gov)
  • Patients are in need of new treatments that can improve survival outcomes, and these positive results support the potential of KEYTRUDA in combination with chemotherapy as a first-line treatment for patients with the most common form of malignant mesothelioma. (merck.com)
  • In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (wikipedia.org)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • The findings support future studies of assessing the safety and efficacy of the novel drug-chemotherapy combination as a maintenance strategy following stem cell transplantation across a range of blood cancers, according to the study authors. (curetoday.com)
  • Maintenance treatment with eprenetapopt, a novel drug, plus the chemotherapy Vidaza (azacitidine) following allogeneic hematopoietic stem cell transplantation was associated with improved survival outcomes in a group of patients with TP53-mutant, high-risk acute myeloid leukemia and myelodysplastic syndromes, according to new study findings. (curetoday.com)
  • Of note, an allogeneic hematopoietic stem cell transplant is a procedure where a patient with cancer receives healthy blood-forming stem cells from a donor to replace their own stem cells that have been damaged by other cancer treatments such as radiation or chemotherapy. (curetoday.com)
  • Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease. (stembook.org)
  • Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC), regardless of PD-L1 expression levels. (advfn.com)
  • We are ecstatic to see Opdivo plus Yervoy continue to demonstrate almost double the overall survival rates as chemotherapy after six years of follow-up - the longest-ever for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer. (advfn.com)
  • In an analysis reported in the Journal of Clinical Oncology , Fenske et al compared outcomes with early or late autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in a population of patients with chemotherapy-sensitive mantle cell lymphoma. (ascopost.com)
  • The study involved analysis of data from 519 patients with chemotherapy-sensitive mantle cell lymphoma receiving transplantations between 1996 and 2007 who were reported to the Center for International Blood and Marrow Transplant Research. (ascopost.com)
  • The early transplantation cohort was defined as patients in first partial or complete remission with no more than two lines of chemotherapy. (ascopost.com)
  • Within the early and late cohorts, the autologous and allogeneic transplantation groups were similar with regard to number of prior lines of chemotherapy and disease status before transplantation. (ascopost.com)
  • Results showed that adding quizartinib to standard chemotherapy with or without allogeneic hematopoietic stem cell transplantation, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival. (medscape.com)
  • 1-4 These survival gains have been attributed largely to advances in biological and genetic characterization of heterogeneous pediatric AML subtypes via next-generation sequencing with clinical outcome correlation, and to enhanced supportive care measures focused on reducing toxicities from intensive multi-agent chemotherapy regimens required for cure. (haematologica.org)
  • Oncogene iASPP enhances self-renewal of hematopoietic stem cells and facilitates their resistance to chemotherapy and irradiation. (nature.com)
  • Now, for the first time, we have evidence that a dual immunotherapy combination showed a superior, sustained overall survival benefit compared to chemotherapy in the first-line treatment of all types of malignant pleural mesothelioma. (bms.com)
  • There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. (oncotarget.com)
  • Treatment includes induction chemotherapy to achieve remission and postremission chemotherapy (with or without stem cell transplantation) to avoid relapse. (msdmanuals.com)
  • A slow clearance of leukemic cells by the initial course of chemotherapy, as measured by the morphologic analysis of peripheral blood or bone marrow smears 1 to 3 weeks from diagnosis, predicts a higher risk of relapse, but can be inaccurate because ALL blast cells are remarkably similar in appearance to bone marrow lymphoid precursors (alias hematogones) and, in some instances, to mature lymphocytes. (ashpublications.org)
  • Study end points were the probabilities of overall survival, leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM) and chronic graft- versus -host disease. (haematologica.org)
  • Despite improvements, mortality after allogeneic hematopoietic cell transplantation (HCT) for nonmalignant diseases remains a significant problem. (duke.edu)
  • Pulmonary complications after hematopoietic cell transplantation (HCT) can lead to significant morbidity and mortality. (duke.edu)
  • In both the early and late cohorts, progression/relapse was lower and nonrelapse mortality was higher in the allogeneic transplant group. (ascopost.com)
  • In the reduced-intensity conditioning allogeneic transplantation group, early transplantation was associated with higher mortality within 2 years (RR = 2.34, P = .017) but lower mortality after 2 years (RR = 0.31, P = .017). (ascopost.com)
  • Transplantation-related issues such as graft versus host disease, graft failure, chronic immunosuppressive therapy, and transplantation-related mortality should be carefully considered prior to proceeding with this approach. (medscape.com)
  • The plain English version would read: "In this two year, open-label trial, our company's antihuman T-lymphocyte immune globulin (ATG) halved the rate of chronic graft-versus-host disease (GVHD) in people who had previously undergone allogeneic haematopoietic stem-cell transplantation, but made no difference to mortality. (bmj.com)
  • Rps14 upregulation promotes inner ear progenitor proliferation and hair cell regeneration in the neonatal mouse cochlea. (stembook.org)
  • Increasing the number of hematopoietic stem and progenitor cells within an umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB transplantation. (duke.edu)
  • Therapeutic Candidate or Device Hematopoietic stem and progenitor cells collected from X-CGD patients modified with a highly regulated lentiviral vector Indication X-linked Chronic Granulomatous Disease Therapeutic Mechanism Lentiviral vector (LV) modification of autologous hematopoietic stem and progenitor cells (HSPCs) to restore physiologic gp91phox expression. (ca.gov)
  • In acute myeloid leukemia (AML), malignant transformation and uncontrolled proliferation of an abnormally differentiated, long-lived myeloid progenitor cell results in high circulating numbers of immature blood cells and replacement of normal marrow by malignant cells. (msdmanuals.com)
  • The mutation occurs in hematopoetic stem cells capable of self renewal and additional mutations are associated with clonal progression may occur in progenitor cells conferring a self renewal capability. (standardofcare.com)
  • The paradox is that the mutation provides advantage at the stem cell level and progenitor cells, with a disadvantage at the level of hematopoietic precursors. (standardofcare.com)
  • Likewise, these cells give rise to progenitor cells committed to a particular cell lineage, and play a crucial role in tissue repair and homeostasis. (bvsalud.org)
  • In this long-term survival analysis of adult alloHSCT recipients, one of the only to include follow-up to 15 years, our results show that women survive significantly longer than men irrespective of their age at transplantation . (bvsalud.org)
  • The early transplantation cohort had a median time from diagnosis to transplantation of 7 months in autologous transplantation recipients and 9 months in allogeneic transplantation recipients, compared with 19 and 30 months in the late transplantation cohort. (ascopost.com)
  • Among autologous transplantation recipients, 5-year overall survival was 75% in patients with first complete response with one line of pretransplantation therapy, 70% in those with first complete response with two lines of therapy, and 38% in those with primary induction failure-sensitive disease (partial remission with no history of complete response). (ascopost.com)
  • In May 2010, the Sixty-third World Health Assembly adopted resolution WHA63.22,1 in which it endorsed the updated WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation and provided strategic directions to support progress in human organ, tissue and cell donation with the aim of maximizing the benefits of transplantation, meeting the needs of recipients, protecting donors and ensuring the dignity of all involved. (who.int)
  • Corneal disease (scarring or perforation) can be successfully addressed through transplantation in 80% of affected individuals.3 Tissue transplantation allows many recipients to return to economically productive lives and promotes their independence. (who.int)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
  • Cytomegalovirus glycoprotein B and N genotypes in pediatric recipients of the hematopoietic stem cell transplant. (cdc.gov)
  • With the increase in organ transplantation and improved survival of transplant recipients, the incidence of disease will likely increase in the coming years. (cdc.gov)
  • Therapeutic Candidate or Device OSSM007: cryopreserved, interferon-gamma-primed bone marrow mesenchymal stem cells (BM-MSC) Indication acute Graft versus host disease (aGVHD) resulting from hematopoietic cell transplantation Therapeutic Mechanism Immunomodulation of host-reactive T cells to induce operational tolerance of donor HSC-derived lymphocytes through direct cell-to-cell contact and secreted paracrine factors. (ca.gov)
  • Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. (stembook.org)
  • Genetic profiling revealed that molecular subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for MDS may inform prognostic stratification and the selection of conditioning regimen. (ascopost.com)
  • Recent study results demonstrated that FLAG-IDA plus venetoclax represents an effective intensive induction regimen for ND-AML and relapsed/refractory AML (R/R-AML), with particular utility as a bridge to allogeneic stem cell transplantation in the R/R-AML population. (bjh.be)
  • In this publication, she shows that adding venetoclax to FLAG-IDA is a safe regimen, associated with deep remissions and successive transplantation. (bjh.be)
  • Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin plus venetoclax represents an effective intensive treatment regimen in ND-AML and R/R-AML patients, associated with deep remissions and a high rate of transition to successful transplantation. (bjh.be)
  • Correction of immunodeficiency associated with NEMO mutation by umbilical cord blood transplantation using a reduced-intensity conditioning regimen. (lu.se)
  • Quizartinib and its active metabolite (AC886) inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. (medscape.com)
  • Recent study showed that iASPP could impact the proliferation and apoptosis of leukemia cells by interacting with FHL2 . (nature.com)
  • Jude CD, Gaudet JJ, Speck NA, Ernst P. Leukemia and hematopoietic stem cells: balancing proliferation and quiescence. (nature.com)
  • Cell proliferation and invasion were assayed using the kidney cell lines HEK293 with wild-type p53 and a ccRCC cell line MZ1257RC mutated for p53. (frontiersin.org)
  • HEK293 cells demonstrated a restriction of ERV-K113 env expression and invasion with no changes in proliferation in the absence of Aza. (frontiersin.org)
  • Abnormal proliferation, clonal expansion, aberrant differentiation, and diminished apoptosis (programmed cell death) lead to replacement of normal blood elements with malignant cells. (msdmanuals.com)
  • There is clonal proliferation of malignant hematopoietic stem cells, dysregulated cellular differentiation, and compromised tissue function. (standardofcare.com)
  • Inactivation of tumor suppressor genes, whose products normally provide negative control of cell proliferation, contributes to malignant transformation in various cell types. (medscape.com)
  • Second, the rapid proliferation of these cells, along with a reduction in their ability to undergo programmed cell death (apoptosis), results in their accumulation in the bone marrow, the blood, and, frequently, the spleen and liver. (medscape.com)
  • Haematopoietic stem cell transplants have been performed in more than 1 500 000 patients (both autologous and allogeneic) to date.1 Although haematological cancers remain the main indication, haematopoietic stem cell transplants are increasingly considered in the treatment of non-malignant disorders and genetic diseases such as haemoglobinopathies (sickle cell anaemia, thalassaemia) that can benefit greatly from this type of transplant. (who.int)
  • As survival following the procedure has increased, its use has expanded beyond cancer to autoimmune diseases and hereditary skeletal dysplasias, notably malignant infantile osteopetrosis and mucopolysaccharidosis. (wikipedia.org)
  • PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) demonstrated a significant improvement in overall survival (OS) in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM) in the Phase 3 CheckMate -743 clinical trial. (bms.com)
  • An aggressive cancer with a five-year survival rate of less than 10 percent, malignant pleural mesothelioma has shown resistance to many clinical treatments," said Paul Baas, M.D., Ph.D., Department of Thoracic Oncology, Netherlands Cancer Institute and the University of Leiden. (bms.com)
  • These data in malignant pleural mesothelioma follow on the established long-term efficacy of Opdivo plus Yervoy in patients with non-small cell lung cancer and further demonstrate the combination's potential to change survival expectations in thoracic cancers," said Sabine Maier, Vice President, Oncology Clinical Development, Bristol Myers Squibb. (bms.com)
  • For more than 15 years, no new systemic treatment options that can extend survival have been approved for patients with malignant pleural mesothelioma. (bms.com)
  • Acute myeloid leukemia (AML) is a heterogeneous disease in terms of genetic basis, clinical, biological and prognostic, and is a malignant clonal disease of leukemia stem cells (LSCs). (biomedcentral.com)
  • Загальні відомості про лейкоз Leukemia is a malignant condition involving the excess production of immature or abnormal leukocytes, which eventually suppresses the production of normal blood cells and results in symptoms. (msdmanuals.com)
  • Malignant transformation usually occurs at the pluripotent stem cell level, although it sometimes involves a committed stem cell with more limited capacity for self-renewal. (msdmanuals.com)
  • The diagnosis of BPDCN is based on the characteristic cytology and immunophenotype of malignant cells coexpressing CD4, CD56, CD123, blood dendritic cell antigens 2 and 4, and CD2AP markers. (elsevierpure.com)
  • Acute myelogenous leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development. (medscape.com)
  • They conducted a phase 2, multicenter trial to analyze if post-transplant eprenetapopt plus Vidaza improved relapse-free survival (which is the length of time following completion of primary treatment that a patient survives without signs or symptoms of that cancer). (curetoday.com)
  • Based on prior results, the study investigators determined that a one-year relapse-free survival rate of 50% or greater would be considered successful. (curetoday.com)
  • The survival rate was similar in the two groups, but the rate of a composite end point of chronic GVHD-free survival and relapse-free survival was higher with ATG. (bmj.com)
  • Therapeutic Candidate or Device TriLeukeVax, an autologous AML vaccine designed to stimulate induction of anti-leukemic cytolytic activity and improve relapse free survival (RFS). (ca.gov)
  • Umbilical cord blood stem cell transplantation (UCBSCT) offers several advantages, including ready availability of the unit, a lower risk of transmitting viral diseases, no risk to the donor, and a lower risk of GVHD even in the absence of a perfect HLA match. (medscape.com)
  • The inclusion of ATG resulted in a significantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG. (bmj.com)
  • The patients with "aggressive" GVHD prophylaxis are the most likely candidates for cell therapy. (cttjournal.com)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • The relationship between the oral and gut microbiome of pediatric patients with hematologic disorders and Graft-versus-Host Disease (GVHD) after transplantation. (who.int)
  • Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. (duke.edu)
  • This retrospective analysis was conducted in a large academic medical center in Germany to gain insights into the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) who underwent allogeneic stem-cell transplantation (allo-SCT) consolidation after first morphologic complete remission (CR)/CR with incomplete recovery (CRi) (CR1/CR1i) or after second CR/CRi (CR2/CR2i) achieved following first relapse. (oncpracticemanagement.com)
  • Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. (oncotarget.com)
  • Secondary endpoints include event-free survival, post-induction rates of complete remission (CR) and composite complete remission (CRc), and the percentage of patients who achieve CR or CRc with FLT3 -ITD measurable residual disease negativity. (ntb.no)
  • Allogeneic hematopoietic stem cell transplantation, particularly when performed during the first remission, may produce durable remissions in selected adults. (elsevierpure.com)
  • In 2014, according to the World Marrow Donor Association, stem-cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone-marrow donations, 12,506 peripheral blood stem-cell donations, and 3,949 cord-blood units). (wikipedia.org)
  • The overall response rate to first-line therapies with anthracycline-based regimens was poor (32%), with a median survival of only 6.9 months. (oncotarget.com)
  • A complete or partial response to first-line regimens was associated with better survival. (oncotarget.com)
  • Intestinal aGvHD can occur after stem cell transplantation when the immune cells of the donor (the graft) consider the recipient's body (the host) as foreign and attack the organs and tissue. (businesswire.com)
  • In addition, we are committed to graft engineering and vaccine development to enhance the ability of transplantation to control blood diseases. (harvard.edu)
  • median survival is less than 24 months 4 - 6 The best therapeutic option has not yet been established. (haematologica.org)
  • Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
  • Therapeutic Candidate or Device Allogeneic iPSC derived dopamine progenitors delivered to the brain of Parkinson's disease patients Indication Idiopathic Parkinson's disease Therapeutic Mechanism The cellular product reconstitutes dopaminergic neuron circuits lost owing to the disease Unmet Medical Need There are currently disease modifying therapies. (ca.gov)
  • Therapeutic Candidate or Device Autologous hematopoietic stem cells transduced with a HexA/HexB expressing lentiviral vector Indication Tay-Sachs disease Therapeutic Mechanism The transplanted gene modified autologous hematopoietic stem cells will engraft in the bone marrow and start producing HexA/HexB expressing immune progeny. (ca.gov)
  • Therapeutic Candidate or Device Autologous blood stem cells edited to restore iduronidase expression Indication Severe Mucopolysaccharidosis Type 1 (MPS1/ Hurler's syndrome) Therapeutic Mechanism Autologous blood stem cells undergo genome editing to restore the production of the missing enzyme. (ca.gov)
  • Life expectancy for long-term survivors of allogeneic hematopoietic stem cell transplantation (alloHSCT), defined as those living ≥5 years post- transplantation , is significantly lower compared with that of the age-matched general population despite a relatively low primary disease relapse rate at >2 years post- transplantation . (bvsalud.org)
  • He has published significantly on this topic including recently in highly regarded journals including Leukemia and Haematologica and these work form the foundation of the clinical trials that he is bringing to patients in order to improve their quality of life and survival. (moffitt.org)
  • Survival was significantly better for both procedures when transplantation occurred earlier in the disease course. (ascopost.com)
  • Survival was significantly better in patients in the early cohort among both autologous ( P = .004) and allogeneic transplantation patients ( P = .005). (ascopost.com)
  • On multivariate analysis of overall survival from the time of diagnosis, stem cell transplantation beyond first complete response, greater age (≥ 60 years), no rituximab prior to transplantation, and increased lactate dehydrogenase at diagnosis were associated with significantly inferior survival. (ascopost.com)
  • Patients with high expressions of FHL2 and iASPP had significantly shorter event-free survival (EFS) and overall survival (OS) than patients with low expressions ( P = 0.005, P = 0.003, respectively). (nature.com)
  • High ERV-K env total protein expression of all tumor subtypes significantly correlated with low tumor grading and a longer disease specific survival using multivariable analyses. (frontiersin.org)
  • Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. (stembook.org)
  • Therefore, this trial evaluates the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, combined with the B-cell lymphoma-2 inhibitor venetoclax in newly diagnosed AML (ND-AML) and relapsed/refractory AML (R/R-AML). (bjh.be)
  • In July 2019, the US Food and Drug Administration (FDA) approved selinexor in combination with low-dose dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM) and in June 2020 approved selinexor as a single-agent for the treatment of relapsed/refractory diffuse large B-cell lymphoma (RR DLBCL). (antengene.com)
  • While these measures have improved event-free survival (EFS) for children and adolescents/young adults with de novo AML, 30-40% of patients ultimately relapse. (haematologica.org)
  • The primary study endpoint was 3-year event-free survival (EFS) following induction. (cancertherapyadvisor.com)
  • We examined the influence of patient sex and donor -recipient sex matching on overall survival (OS) in a landmark analysis of long-term survivors . (bvsalud.org)
  • This outcome is independent of other common pretransplantation prognostic indicators , such as donor sex or performance status at transplantation . (bvsalud.org)
  • It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). (wikipedia.org)
  • Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation. (stembook.org)
  • Hematopoietic stem cell transplantation from an infected SARS-CoV2 haploidentical donor: A case report. (stembook.org)
  • Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, de Lima M, Lichtiger B " Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. . (bcm.edu)
  • [ 14 ] The first successful allogeneic stem cell transplant from an HLA-identical sibling donor was reported in 1982. (medscape.com)
  • The primary purpose of this study is to estimate and compare overall survival between the two arms: patients who are Very Likely to find a Matched Unrelated Donor (MUD) versus those who are Very Unlikely to find a MUD. (mayo.edu)
  • TP53 mutation was associated with poorer overall survival and increased risk of relapse. (ascopost.com)
  • 6 Approximately 80% of FLT3 mutations are FLT3 -ITD mutations, which drive cancer growth and contribute to particularly unfavorable prognosis including increased risk of relapse and shorter overall survival. (ntb.no)
  • The genes encoding the components of the T-cell receptors undergo a similar process in T-cell precursors. (ashpublications.org)
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
  • Disease relapse is the primary reason why allogeneic hematopoietic stem cell transplants fail, according to the study authors, who noted that novel strategies for stem cell transplant to reduce the risk for disease relapse are severely needed. (curetoday.com)
  • This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort. (oncotarget.com)
  • Stem Cell Rev Rep. 2023. (stembook.org)
  • Our results presented at WCLC 2023 build on our legacy of transforming survival expectations with immunotherapy combinations. (advfn.com)
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. (oncotarget.com)
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare mature T-cell malignancy first described in Japan in 1977 [ 1 ]. (oncotarget.com)
  • Methods: A search of PubMed and Medline was conducted for English-written articles relating to BPDCN, CD4 + CD56 + hematodermic neoplasm, and blastic natural killer cell lymphoma. (elsevierpure.com)
  • Most patients with BPDCN have skin lesions and simultaneous involvement of the peripheral blood, bone marrow, and lymph nodes.Methods: A search of PubMed and Medline was conducted for English-written articles relating to BPDCN, CD4+CD56+ hematodermic neoplasm, and blastic natural killer cell lymphoma. (elsevierpure.com)
  • HR=2.64, 95%CI: 1.05-6.63, P =0.04, respectively), while a CR status at transplant was associated with improved leukemia-free survival (HR=0.44, 95%CI: 0.22-0.88, P =0.02). (haematologica.org)
  • Currently, maintenance strategies (which are used to reduce the risk for disease recurrence) are not standard of care in allogeneic (hematopoietic stem cell transplant) for (acute myeloid leukemia and myelodysplastic syndromes)," the study authors wrote. (curetoday.com)
  • Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia. (stembook.org)
  • The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation. (stembook.org)
  • As an example, Dr. Sallman has focused research and clinical trial efforts on patients who have TP53 mutation (often associated with complex genes/cytogenetics) given their high risk of transformation to acute leukemia and poor survival. (moffitt.org)
  • Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. (duke.edu)
  • FHL2 interacts with iASPP and impacts the biological functions of leukemia cells. (nature.com)
  • Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. (qxmd.com)
  • A heterogenous group of myeloid disorders characterized by somatically mutated hematopoietic stem cells,the presence of variable peripheral cytopenias, and a broad risk of progression to acute myeloid leukemia (AML). (standardofcare.com)
  • ALL cells can be recognized by their clonal rearrangement of immunoglobulin and T-cell receptor genes, expression of gene fusions, and leukemia-associated immunophenotypes. (ashpublications.org)
  • The first demonstration that bone marrow samples apparently devoid of ALL cells may, in fact, contain measurable levels of leukemia (ie, "minimal residual disease" or MRD) was provided soon after the advent of polyclonal antisera against leukocyte antigens: combinations of cell markers were used to distinguish T-lineage ALL cells from normal immature and mature lymphocytes by immunofluorescence microscopy. (ashpublications.org)
  • The disease is primarily characterized by fibrosis in the bone marrow, extramedullary hematopoiesis, anemia, splenomegaly, constitutional symptoms, and possible progression to leukemia that would shorten patients' survival. (antengene.com)
  • Among several factors, patient sex is increasingly recognized as a prognostic indicator of long-term survival . (bvsalud.org)
  • Based on these results, it was concluded that MRD status at allo-SCT and the number of remissions prior to transplantation were important independent prognostic factors in patients with AML. (oncpracticemanagement.com)
  • This study supports ERV-K env as a single prognostic indicator for better survival of RCC, which we propose represents a new tumor antigen. (frontiersin.org)
  • Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G " An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. . (bcm.edu)
  • The present report aims to provide a comprehensive analysis of the current situation and facilitate a forward-looking discussion on actions for improving access to transplantation therapies. (who.int)
  • These results indicate that maintenance therapies using hypomethylating agents could reduce the risk of post-transplant recurrence, resulting into remarkable superior survival. (qxmd.com)
  • I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). (dukecancerinstitute.org)
  • Likewise, the knowledge of stem cell biology is crucial to the development of stem cell therapies, based on tissue engineering applied to dentistry, seeking the regeneration of dental tissues damaged or lost by caries, trauma or genetic diseases. (bvsalud.org)
  • Therapies based on the application of stem cells have great potential in the prevention and treatment of several diseases, such as cancer, diabetes, cardiovascular disease, spinal cord injuries, neurological diseases such as Parkinson's and Alzheimer's, and in the regeneration of various tissues and organs. (bvsalud.org)
  • However, further studies are required to gain complete understanding of stem cell biology, which is fundamental for the development of successful cell-based therapies 1-3 . (bvsalud.org)
  • Kamble RT, Guo S, Ramos CA, Carrum G " Acute gout at engraftment following hematopoietic transplantation. . (bcm.edu)
  • Despite the fact that most follicular lymphomas are advanced at the time of diagnosis, many patients may not require treatment for prolonged periods of time, and the median survival of patients with follicular lymphomas has historically been approximately 8-10 years. (medscape.com)
  • Adverse mutations are present in approximately 20% of patients with very low risk MDS with a median survival nearly one third shorter than that have low-risk patients without these mutations. (standardofcare.com)
  • Median survival rates ranged between 12 and 16 months. (elsevierpure.com)
  • Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. (duke.edu)
  • Candidates for HSCTs include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia with defective stem cells, and also children or adults with aplastic anemia who have lost their stem cells after birth. (wikipedia.org)
  • Allogeneic stem cell transplantation in a patient with the Wiskott-Aldrich syndrome. (alliedacademies.org)
  • Understanding how stem cells behave in the niche is extremely important in order to extract these cells from their natural habitat, expand them in vitro and transplant the stem cells back to the patient, to repair and/or regenerate tissues and organs, with no risks to the individual's integrity. (bvsalud.org)
  • Clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias. (standardofcare.com)
  • Criteria for diagnosis of MDS consist of anemia, thrombocytopenia, or neutropenia that persist for six months or longer, dysplasia greater than 10% in at least one bone marrow cell lineage, and MDS associated clonal cytogenetic abnormalities or molecular markers. (standardofcare.com)
  • The clonal outgrowth of mutant stem cells favors and abnormal hematopoietic stem cell niche. (standardofcare.com)
  • Because ALL cells arise from the oncogenic transformation of a single lymphoid precursor, they have clonal antigen-receptor (immunoglobulin and/or T-cell receptor) gene rearrangements in most cases, which can be used to distinguish ALL cells from normal lymphoid cells (expressing gene rearrangements with different sequences) and nonlymphoid cells (lacking the rearrangements). (ashpublications.org)
  • The American Society for Transplantation and Cellular Therapy (ASTCT) guidelines recommend a collection target of 3-5 × 10 6 CD34+ cells/kg. (medscape.com)
  • The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
  • Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products. (bloodcancerstoday.com)
  • Transient hemophagocytosis with deficient cellular cytotoxicity, monoclonal immunoglobulin M gammopathy, increased T-cell numbers, and hypomorphic NEMO mutation. (lu.se)
  • With these six-year results, we are seeing remarkably sustained and durable clinical survival benefits with nivolumab plus ipilimumab year-over-year," said Solange Peters, M.D., Ph.D., professor and chair of medical oncology and the thoracic malignancies program in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. (advfn.com)
  • Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with an aggressive clinical course. (elsevierpure.com)
  • Assays based on polymerase chain reaction or flow cytometry can detect one ALL cell among 10,000 to 100,000 normal cells in clinical samples. (ashpublications.org)
  • The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. (duke.edu)
  • [ 16 ] This group's research documented a 90% long-term survival rate in patients with favorable characteristics (young age, HLA match, no organ dysfunction). (medscape.com)
  • Organ transplantation is often the best, if not the only, treatment for acute and chronic organ failure. (who.int)
  • Patients with AML present with symptoms resulting from bone marrow failure, symptoms resulting from organ infiltration with leukemic cells, or both. (medscape.com)
  • The aim of this study is thus to define group-based trajectory modeling, to identify clusters of individual serum citrulline kinetics in the early phase of allogeneic HCST, and to test whether these unsupervised trajectories were correlated with these early complications. (confex.com)
  • Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. (duke.edu)
  • Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside. (stembook.org)
  • The deduced probable HLA-C*03:187-associated human leukocyte antigen haplotype (A*24:02-B*35:01-C*03:187-DRB1*11:01) revealed in Taiwanese unrelated hematopoietic bone marrow stem cell donors. (cdc.gov)
  • Our scientists pursue every aspect of cancer research-from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more. (mskcc.org)
  • Kreso A, Dick J. Evolution of the cancer stem cell model. (nature.com)
  • The expression level of NCALD gene was associated with the prognosis of ovarian cancer and non-small cell lung cancer (NSCLC). (biomedcentral.com)
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (wikipedia.org)
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
  • There were four serious cases of fever and two serious cases each of febrile neutropenia (fever during a period of low white blood cell count) and difficult or labored breathing. (curetoday.com)
  • A complete blood cell count (CBC) with differential should be obtained, including examination of the peripheral blood smear if the differential is abnormal. (medscape.com)
  • Motixafortide is indicated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. (medscape.com)
  • Transfusion of washed, leukocyte-poor red blood cells (RBCs) at approximately 8-15 mL RBCs per kilogram (kg) of body weight over 1-2 hours is recommended. (medscape.com)
  • The study involved targeted mutational analysis of samples obtained before stem cell transplant from 1,514 MDS patients enrolled at the Center for International Blood and Marrow Transplant Research Repository between 2005 and 2014. (ascopost.com)
  • Leukocyte cell suspension after preliminary red blood cells lysis were incubated with a protein tyrosine kinase inhibitor (Dasatinib) for 1 hour at 37°С in order to increase surface expression of both TCR and CD8. (cttjournal.com)
  • Two-platform method was used to calculate absolute CMV (NLV/TPR)-specific CD3+CD8+ cell counts in peripheral blood. (cttjournal.com)
  • First, the production of normal blood cells markedly decreases, which results in varying degrees of anemia , thrombocytopenia , and neutropenia . (medscape.com)
  • Immunologic variations from the norm of WAS incorporate T-cell lymphopenia, flawed proliferative reaction to CD3 cross-linking, disabled counter acting agent reaction to polysaccharide antigens, flawed monocyte chemotaxis, anomalies of fortified dendritic cells, and an expanded lymphocyte apoptosis with age. (alliedacademies.org)
  • The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. (nature.com)
  • The MDS cell of origin is a hematopoetic stem cell that proliferates and escapes apoptosis. (standardofcare.com)
  • The TP53 gene is also capable of stimulating apoptosis of cells containing damaged DNA. (medscape.com)
  • TP53 activates the expression of genes involved in apoptosis, cell cycle regulation (p21), and MDM2. (medscape.com)